ATE229814T1 - Verwendung von il-10 zur wundheilung mit verminderter narbenbildung - Google Patents

Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Info

Publication number
ATE229814T1
ATE229814T1 AT96926507T AT96926507T ATE229814T1 AT E229814 T1 ATE229814 T1 AT E229814T1 AT 96926507 T AT96926507 T AT 96926507T AT 96926507 T AT96926507 T AT 96926507T AT E229814 T1 ATE229814 T1 AT E229814T1
Authority
AT
Austria
Prior art keywords
wound healing
reduced
scaring
reduced scaring
healing
Prior art date
Application number
AT96926507T
Other languages
German (de)
English (en)
Inventor
Mark William James Ba Ferguson
High Peak Vale
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of ATE229814T1 publication Critical patent/ATE229814T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96926507T 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung ATE229814T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (1)

Publication Number Publication Date
ATE229814T1 true ATE229814T1 (de) 2003-01-15

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926507T ATE229814T1 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505219A (ja) * 1996-12-04 2001-04-17 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター 創傷の治癒および線維症の治療
WO1998033516A1 (en) * 1997-02-05 1998-08-06 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
AU6951300A (en) * 1999-09-08 2001-04-10 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
KR20150072458A (ko) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
MX2010010431A (es) * 2008-03-25 2010-11-25 Paloma Pharmaceuticals Inc Metodos para tratar desordenes fibroticos.
CN102256625B (zh) 2008-12-17 2013-11-20 默沙东公司 单和双peg il10的生产和用途
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20140112898A1 (en) * 2011-03-31 2014-04-24 President And Fellows Of Harvard College Unique population of regulatory t cells that regulate tissue regeneration and wound healing
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (en) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Membrane structure coated with low pI protein and methods of making and using
EP0454736A4 (en) * 1989-01-20 1993-05-12 The University Of Melbourne Fibrinolysis
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
ATE171625T1 (de) 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
ES2085003T3 (es) * 1991-01-10 1996-05-16 Schering Corp Uso de il-4 para mejorar la fase reparadora de la curacion y restaño de heridas y para mejorar la curacion de heridas infectadas y las heridas de mamiferos diabeticos.
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
NZ269663A (en) 1993-07-26 1997-09-22 Schering Corp Agonists and antagonists of il-10
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
US6387364B1 (en) 2002-05-14
ZA966744B (en) 1998-02-09
JPH11510505A (ja) 1999-09-14
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
JP4050317B2 (ja) 2008-02-20
EP0871473B1 (en) 2002-12-18
DE69625516T2 (de) 2003-09-25
EP0871473A1 (en) 1998-10-21
DK0871473T3 (da) 2003-04-14
CA2229078C (en) 2010-04-20
ES2187665T3 (es) 2003-06-16
AU719089B2 (en) 2000-05-04
GB2304047A (en) 1997-03-12
GB9516287D0 (en) 1995-10-11
PT871473E (pt) 2003-03-31
CA2229078A1 (en) 1997-02-20
WO1997005894A1 (en) 1997-02-20
US7052684B2 (en) 2006-05-30
DE69625516D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
ATE229814T1 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
ATE395022T1 (de) Zusammensetzung und verfahren zur beschleunigung von wunden- und brandheilung
DE69524682D1 (de) Mittel zur Behandlung von Wunden
WO2000073418A3 (en) A method of using autologous fibroblasts to promote healing of wounds and fistulas
DE69533166D1 (de) Polymerer wundheilungsbeschleuniger
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE512650T1 (de) Hydrogelwundverband und zugehöriges herstellungs- und benutzungsverfahren
ATE279916T1 (de) Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
DE69329559D1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
ATE173917T1 (de) Mittel zur äusserlichen anwendung von antiseptika und/oder wundheilungsfördernder stoffe
ATE298579T1 (de) Phosphnatanaloge von mannose-6-phosphate und deren verwendung zur förderung der heilung von wunden oder fibrotischen störungen mit verminderter narbenbildung
ATE369880T1 (de) Mediziniscer verband
DE69624214D1 (de) Hormonale medikamente und deren verwendung zur behebung von östrogenmangelerscheinungen
ATE227995T1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
ATE202787T1 (de) Makroskopisch orientiertes zelladhäsionsprotein zur wundbehandlung
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung
ATE320284T1 (de) Verwendung von mindestens einem derivat der 10- hydroxy-2-decenoicsäure in einer zusammensetzung zur förderung der abschuppung der haut
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69931371D1 (de) Methoden zur verbesserung der vaskularisierung und förderung der wundheilung
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69826460D1 (de) Verwendung von niedermolekularen heparinen zur vorbeugung und behandlung von einem trauma des zentralnervensystems
DE69912778D1 (de) Verwendung von wundverbänden zur behandlung von akuten wunden
DE59712374D1 (de) Verwendung von hcc-1 zur behandlung von thrombozytopenien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871473

Country of ref document: EP